The concept of a minimal clinically important difference (MCID) is well established. Here, we
review the evidence base and methods used to define MCIDs as well as their strengths and …

Background Long‐acting bronchodilators such as long‐acting β‐agonist (LABA), long‐
acting muscarinic antagonist (LAMA), and LABA/inhaled corticosteroid (ICS) combinations …

Background Most guidelines recommend either a long-acting beta-agonist (LABA) plus an
inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice …

Background We evaluated the effect of dual, longacting inhaled bronchodilator treatment on
exacerbations in patients with severe and very severe chronic obstructive pulmonary …

We investigated the efficacy and safety of dual bronchodilation with QVA149 versus its
monocomponents indacaterol and glycopyrronium, tiotropium and placebo in patients with …

Rationale: Post hoc analyses suggest that blood eosinophils have potential as a predictive
biomarker of inhaled corticosteroid efficacy in the management of chronic obstructive …

The publication of the Spanish guideline for chronic obstructive pulmonary disease–COPD–
(GesEPOC) has brought about a change in the approach to the treatment of this disease …

Das vorliegende Dokument ist eine Neufassung und Aktualisierung der Leitlinie zur
Diagnostik und Therapie von Patienten mit COPD, die die bisherige Version aus dem Jahr …

Background The efficacy and safety of once-daily (od) fixed-dose combination of indacaterol
(IND), glycopyrronium (GLY) and mometasone furoate (MF) via Breezhaler® versus …

Аннотация В настоящее время хроническая обструктивная болезнь легких (ХОБЛ)
является глобальной проблемой и одной из ведущих причин смерти в мире. Терапия …